Bioactive lipids and human macrophage survival
Treatment (prior to apoptosis induction) . | Caspase-3 activity, fold of control* . | SD . | P, n ≥ 3† . |
|---|---|---|---|
| None | 30.6 | ± 4 | ND |
| ACM | 5.3 | ± 3.6 | .02 |
| LPA | |||
| 1 μM | 30.1 | ± 12.8 | .35 |
| 10 μM | 33.8 | ± 19.7 | .49 |
| 100 μM | 39.5 | ± 20.8 | .35 |
| SIP | |||
| 1 μM | 13.2 | ± 9.2 | .05 |
| 10 μM | 10 | ± 6.3 | .02 |
| 100 μM | 6.1 | ± 4 | .006 |
| PAF | |||
| 1 μM | 40.5 | ± 5.1 | .4 |
| 10 μM | 61.1 | ± 41.3 | .15 |
| 100 μM | 97.2 | ± 59.6 | .09 |
| LPC | |||
| 1 μM | 54.2 | ± 27.8 | .25 |
| 10 μM | 32.1 | ± 18.4 | .44 |
| 100 μM | 20 | ± 5.2 | .2 |
Treatment (prior to apoptosis induction) . | Caspase-3 activity, fold of control* . | SD . | P, n ≥ 3† . |
|---|---|---|---|
| None | 30.6 | ± 4 | ND |
| ACM | 5.3 | ± 3.6 | .02 |
| LPA | |||
| 1 μM | 30.1 | ± 12.8 | .35 |
| 10 μM | 33.8 | ± 19.7 | .49 |
| 100 μM | 39.5 | ± 20.8 | .35 |
| SIP | |||
| 1 μM | 13.2 | ± 9.2 | .05 |
| 10 μM | 10 | ± 6.3 | .02 |
| 100 μM | 6.1 | ± 4 | .006 |
| PAF | |||
| 1 μM | 40.5 | ± 5.1 | .4 |
| 10 μM | 61.1 | ± 41.3 | .15 |
| 100 μM | 97.2 | ± 59.6 | .09 |
| LPC | |||
| 1 μM | 54.2 | ± 27.8 | .25 |
| 10 μM | 32.1 | ± 18.4 | .44 |
| 100 μM | 20 | ± 5.2 | .2 |
ND indicates not determined
Human primary macrophages were exposed to ACM, LPA, S1P, PAF, or LPC at the indicated concentrations for 16 hours. Apoptosis was induced with 10 ng/mL TNF-α and 10 μg/mL CHX for 8 hours. Caspase-3 activity in whole-cell lysates was quantified as described in “Material and methods”
Statistical analysis was performed using the paired Student t test